NASDAQ$RAPT
RAPT Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
RAPT Therapeutics reported financial results for Q3 2023, with a strong cash position maintained.
RAPT Therapeutics reported a net loss of $31.4 million for the third quarter of 2023. Research and development expenses were $27.0 million, and general and administrative expenses were $6.9 million. The company's cash, cash equivalents, and marketable securities totaled $184.8 million as of September 30, 2023, expected to support operations through mid-2025.
- Progress continued with zelnecirnon in inflammatory diseases and tivumecirnon in oncology.
- Top-line data from the Phase 2b trial of zelnecirnon in atopic dermatitis is expected in mid-2024.
- Enrollment is progressing well in the Phase 2a trial of zelnecirnon in asthma.
- Phase 2 data for tivumecirnon in combination with pembrolizumab in checkpoint-naïve non-small cell lung cancer was presented at SITC.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$0
Forward guidance
RAPT Therapeutics anticipates continued clinical development progress and expects its current cash balance to support planned operations through mid-2025.
Tailwinds
- Anticipated reporting of top-line data from Phase 2b trial of zelnecirnon in atopic dermatitis in mid-2024.
- Good progress in enrolling Phase 2a trial in asthma.
- Strong cash balance expected to support planned operations through mid-2025.
- Advancement of zelnecirnon in inflammatory diseases.
- Advancement of tivumecirnon in oncology.
Headwinds
- Unexpected or unfavorable safety or efficacy data during clinical studies.
- Lower than expected enrollment in Phase 2b clinical trial of zelnecirnon in AD.
- Unanticipated or greater than anticipated impacts or delays due to macroeconomic conditions.
- Changes in expected or existing competition.
- Uncertainties and timing of the regulatory approval process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro